Darovasertib worked in metastatic uveal melanoma. Can IDEAYA now stop the cancer from returning?
IDEAYA and Servier begin a 450-patient Phase 3 trial testing whether darovasertib plus crizotinib can prevent uveal melanoma recurrence.
Pharma & Biotech